|Bid||2.95 x 200|
|Ask||5.95 x 300|
|Day's range||5.50 - 5.82|
|52-week range||0.76 - 7.98|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2017 - 14 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.00|
BRISBANE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces that its President & Chief Executive Officer, Peter Maag, received the 2017 Transplant Innovation Award from TRIO.
CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2017.
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline on December 28th, 2017 by Fundamental Markets, please note that the Kinsale Capital Group's Recent Financial Performance section has been amended.
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.
The Brisbane, California-based company said it had a loss of 63 cents per share. Losses, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 15 cents per share. The ...